Dukoral3 ml

Approved Use

Dukoral is indicated for active immunization against cholera caused by Vibrio cholerae serogroup O1 (and, for bivalent formulations, serogroup O139) in individuals living in or travelling to cholera-endemic or epidemic areas.

• Established/guideline-supported use: Primary prevention of cholera in residents of cholera-endemic regions, including as part of WHO-coordinated mass vaccination campaigns during outbreaks or humanitarian emergencies (e.g. displacement camps, flood- or conflict-affected areas with high cholera risk).
• Established use: Pre-travel prophylaxis for adults and children travelling to areas with active cholera transmission, particularly humanitarian workers, healthcare workers, and travelers to remote endemic regions with limited access to safe water and medical care.
• Adjunct role: Dukoral is an adjunct to, and does not replace, standard cholera-prevention measures such as safe drinking water, food hygiene, sanitation, and handwashing, which must be continued regardless of vaccination status.

Dukoral does not protect against illness caused by organisms other than Vibrio cholerae and is not indicated for treatment of active cholera infection.

Each dose of Oral Cholera Vaccine (killed whole-cell formulation) contains formalin- and heat-inactivated whole cells of Vibrio cholerae O1 (including Inaba and Ogawa serotypes, classical and El Tor biotypes) with or without inactivated Vibrio cholerae O139, supplied as an oral liquid suspension. Some formulations are supplied with a buffer sachet or require dilution in clean water immediately before administration; no injectable components are present, and the vaccine contains no adjuvant requiring injection.

Dukoral is a vaccine given by mouth to stimulate active immunity against cholera, an acute diarrheal illness caused by toxin-producing strains of Vibrio cholerae. It belongs to the class of killed (inactivated) whole-cell oral vaccines used worldwide, including in WHO-prequalified mass vaccination programs. Dukoral is supplied as an oral suspension, typically as a pre-filled liquid or as a powder/liquid requiring reconstitution with a diluent or buffer solution before dosing, and is administered as part of a primary immunization series.

Vaccines - Bacterial vaccines - Oral cholera vaccine (inactivated, whole-cell)

Pharmacodynamics

Oral Cholera Vaccine works by exposing the gut mucosa to inactivated Vibrio cholerae whole-cell antigens (and, in some formulations, cholera toxin B subunit antigen), stimulating a local intestinal (mucosal IgA) and systemic (serum vibriocidal antibody) immune response. This immune response reduces the risk of symptomatic cholera on subsequent exposure to toxigenic Vibrio cholerae. Protective vibriocidal antibody titers typically develop within 1-2 weeks after completion of the primary series with Oral Cholera Vaccine.

Pharmacokinetics

Conventional pharmacokinetic parameters (absorption, distribution, metabolism, excretion) are not applicable to Oral Cholera Vaccine, as it acts locally within the gastrointestinal tract to induce immunity rather than being systemically absorbed as an active pharmacologic agent.

Dukoral is given by mouth, not by injection. Depending on the formulation, the vaccine suspension may need to be mixed with a supplied buffer or a specified volume of clean, cool water immediately before the dose is swallowed. Patients should avoid eating or drinking (including breastfeeding, where specified by the product) for about one hour before and after each dose of Dukoral to reduce dilution of the vaccine by stomach contents. If vomiting occurs shortly after a dose, consult a physician about whether the dose should be repeated.

Formal drug-interaction studies with Dukoral are limited. Clinically relevant considerations include:

• Antibiotics: Systemic or oral antibiotics active against Vibrio cholerae taken close to the time of vaccination may reduce the immune response to Dukoral; where possible, vaccination should be separated from antibiotic courses.
• Immunosuppressive therapy: Concurrent immunosuppressive drugs or corticosteroids may blunt the antibody response to Dukoral (see Use in Special Populations).
• Other oral or live vaccines: Co-administration with other live oral vaccines (e.g. oral polio vaccine, oral typhoid vaccine) has not been fully characterized for all products; a spacing interval is often recommended per local immunization guidance. Discuss the full vaccination schedule with a physician or immunization provider.

Most reported reactions to Dukoral are mild and self-limited.

• Common: Abdominal pain, diarrhea, nausea, and loose stools following administration.
• Less common: Low-grade fever, headache, fatigue, or vomiting.
• Rare: Hypersensitivity reactions (rash, urticaria); rare reports of more serious allergic reactions have been described with oral vaccines generally.

Patients should seek medical attention for severe abdominal pain, high fever, signs of an allergic reaction (swelling of the face/throat, difficulty breathing, widespread rash), or symptoms that are severe or persistent after receiving Dukoral.

Pregnancy: Data on the use of Dukoral in pregnancy are limited. As with most vaccines, Dukoral should be used during pregnancy only if clearly needed and if the potential benefit (e.g. protection during a cholera outbreak in a high-risk setting) justifies the potential risk; a physician should be consulted before use in pregnant women. Live-attenuated single-dose Dukoral formulations, where available, are generally not recommended during pregnancy as a precaution.

Lactation: Information on excretion of vaccine components into breast milk is limited; however, killed whole-cell Dukoral is generally considered compatible with breastfeeding. A physician should be consulted before use while breastfeeding.

• Dukoral does not provide 100% protection against cholera; standard food and water safety precautions and hygiene measures must be continued even after completing vaccination.
• The full multi-dose schedule of Dukoral must be completed for optimal protection; missed or delayed doses beyond the recommended interval may require restarting the series per current guidance.
• Protection after Dukoral is time-limited; individuals with continued high-risk exposure may require a booster dose per current guidelines.
• Immunocompromised individuals (e.g. HIV infection, immunosuppressive therapy) may have a reduced immune response to Dukoral (see Use in Special Populations).
• Mild gastrointestinal symptoms such as abdominal pain and diarrhea can occur after vaccination (see Side Effects).
• Vaccination should be deferred, not cancelled, in patients with acute severe febrile or gastrointestinal illness until they recover (see Contraindications).

There is no established clinical scenario of vaccine "overdose" in the way that applies to standard medications, since Dukoral is given as a defined single-dose volume. If a dose larger than intended is inadvertently administered, or if a person receives doses more frequently than recommended, they should be monitored for gastrointestinal or allergic symptoms and should contact a physician, seek immediate medical attention, or contact emergency/poison control services if symptoms are severe or concerning.

Elderly

No specific dose adjustment of Dukoral is established for elderly patients; immune response may be somewhat reduced with advanced age, consistent with general immunosenescence.

Immunocompromised individuals

Patients with HIV infection, other causes of immunosuppression, or those receiving immunosuppressive therapy may mount a reduced antibody response to Dukoral; vaccination may still be considered where the benefit of partial protection outweighs the risk, but this should be individualized with a physician.

Chronic gastrointestinal disease

Use with caution and physician guidance in individuals with chronic gastrointestinal disorders, as the mucosal immune response to Dukoral may be altered.

Some formulations of Dukoral are supplied as a liquid vaccine sachet/vial together with a separate effervescent buffer granule sachet. Immediately before dosing, dissolve the buffer sachet in the specified volume of clean, cool (not hot) water as directed on the product labeling, then add the vaccine suspension to the buffered solution and have the patient drink the entire mixture promptly. For pediatric doses, the buffer may need to be further diluted with additional water per the manufacturer's instructions. Formulations that do not require a buffer are given directly as supplied; always follow the specific product's reconstitution instructions.

Vaccines; Bacterial vaccines; Enteric/oral vaccines; Cholera vaccines (inactivated whole-cell or live-attenuated, oral)

Oral Cholera Vaccine induces active immunity by presenting inactivated (or, in some formulations, live-attenuated) Vibrio cholerae antigens to the gut-associated lymphoid tissue, generating intestinal mucosal IgA and systemic vibriocidal antibodies directed against Vibrio cholerae O1 and/or O139 lipopolysaccharide and, where present, cholera toxin B subunit. This antibody response reduces the likelihood of colonization and toxin-mediated symptomatic disease upon subsequent exposure to toxigenic Vibrio cholerae.

Dukoral (killed whole-cell formulations) is approved for use in children from 1 year of age in most WHO-prequalified products, with a 2-dose primary series; dosing/dilution may differ for children 1 to under 2 years versus older children and adults, per product labeling. Safety and efficacy of Dukoral in infants younger than 1 year have not been established, and it should not be given to this age group outside specific guidance. Single-dose live-attenuated Dukoral formulations, where available, are typically approved for a narrower age range (commonly 2 years and older); safety and efficacy outside the approved age range have not been established.